Powered by a data-driven AI platform, Aureka is building a scalable internal pipeline with lead programs centered on high-value, differentiated antibody therapeutics treating cardiometabolic and inflammatory diseases.

In addition, Aureka is seeking strategic partners who can support our vision to build an enduring and scalable tech-bio franchise. With multiple large biopharma, Aureka's platform has been validated to discover best-in-class antibody therapeutics that would otherwise be difficult to obtain with traditional methods.

Our platform can uniquely enable function-first antibody design, supporting high-value applications such as receptor agonists, pH-dependent recycling antibodies, internalizing biparatopic antibodies for ADCs, and epitope-specific approaches to challenging targets including promiscuous receptors and GPCRs.